Recent advances in managing and understanding nephrolithiasis/nephrocalcinosis

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN are considered to be on the same spectrum of diseases with different severities. They are classified by the percentage of skin detachment area. SJS/TEN can also cause several complications in the liver, kidneys, and respiratory tract. The pathogenesis of SJS/TEN is still unclear. Although it is difficult to diagnose early stage SJS/TEN, biomarkers for diagnosis or severity prediction have not been well established. Furthermore, optimal therapeutic options for SJS/TEN are still controversial. Several drugs, such as carbamazepine and allopurinol, are reported to have a strong relationship with a specific human leukocyte antigen (HLA) type. This relationship differs between different ethnicities. Recently, the usefulness of HLA screening before administering specific drugs to decrease the incidence of SJS/TEN has been investigated. Skin detachment in SJS/TEN skin lesions is caused by extensive epidermal cell death, which has been considered to be apoptosis via the Fas-FasL pathway or perforin/granzyme pathway. We reported that necroptosis, i.e. programmed necrosis, also contributes to epidermal cell death. Annexin A1, released from monocytes, and its interaction with the formyl peptide receptor 1 induce necroptosis. Several diagnostic or prognostic biomarkers for SJS/TEN have been reported, such as CCL-27, IL-15, galectin-7, and RIP3. Supportive care is recommended for the treatment of SJS/TEN. However, optimal therapeutic options such as systemic corticosteroids, intravenous immunoglobulin, cyclosporine, and TNF-α antagonists are still controversial. Recently, the beneficial effects of cyclosporine and TNF-α antagonists have been explored. In this review, we discuss recent advances in the pathophysiology and management of SJS/TEN.

[1]  R. Abe,et al.  RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2020, The journal of allergy and clinical immunology. In practice.

[2]  T. Nomura,et al.  Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. , 2019, The journal of allergy and clinical immunology. In practice.

[3]  W. Garner,et al.  Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2019, Burns : journal of the International Society for Burn Injuries.

[4]  S. Mallal,et al.  Identification of drug-specific public TCR driving severe cutaneous adverse reactions , 2019, Nature Communications.

[5]  K. Mounzer,et al.  HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study , 2019, AIDS Research and Therapy.

[6]  D. Kroshinsky,et al.  Use of Cyclosporine for the treatment of Steven Johnson Syndrome/ Toxic Epidermal Necrolysis. , 2019, Journal of the American Academy of Dermatology.

[7]  L. Scherrer,et al.  Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2018, Dermatologic therapy.

[8]  F. Wang,et al.  Diverse expression of TNF-α and CCL27 in serum and blister of Stevens–Johnson syndrome/toxic epidermal necrolysis , 2018, Clinical and Translational Allergy.

[9]  W. Yeo,et al.  A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis , 2018, Journal of inflammation research.

[10]  T. Harr,et al.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , 2018, Clinical Reviews in Allergy & Immunology.

[11]  Qi Guo,et al.  Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study , 2017, Journal of critical care.

[12]  E. Ramírez,et al.  Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. , 2017, The Journal of investigative dermatology.

[13]  M. Mockenhaupt,et al.  New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.

[14]  Kuang-Hui Yu,et al.  Diagnostic utility of HLA‐B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta‐analysis , 2017, International journal of rheumatic diseases.

[15]  C. Ng,et al.  HLA-A*31: 01 and HLA-B*15:02 association with Stevens–Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population , 2017, Pharmacogenetics and genomics.

[16]  H. Chuang,et al.  Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions , 2017, The Journal of Rheumatology.

[17]  M. Schumacher,et al.  Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis , 2017, JAMA dermatology.

[18]  C. Ng,et al.  HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions , 2017, Neurology.

[19]  M. Schumacher,et al.  Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.

[20]  Veronika Vidova,et al.  A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. , 2017, Analytica chimica acta.

[21]  Philip R. Cohen,et al.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures , 2017, Advances in Therapy.

[22]  Hyon K. Choi,et al.  The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. , 2017, Seminars in arthritis and rheumatism.

[23]  Z. Liu,et al.  A study of HLA‐B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN , 2017, HLA.

[24]  T. Kuo,et al.  Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians , 2017, Neurology.

[25]  Lei Yu,et al.  Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies , 2016, Oncotarget.

[26]  C. Sukasem,et al.  HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand , 2016, Front. Pharmacol..

[27]  J. Silverberg,et al.  Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, Journal of Investigative Dermatology.

[28]  W. Chung,et al.  Severe cutaneous adverse drug reactions , 2016, The Journal of dermatology.

[29]  P. Dziewulski,et al.  U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.

[30]  P. Dziewulski,et al.  UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[31]  C. Ng,et al.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population , 2016, The Pharmacogenomics Journal.

[32]  G. Gambaro,et al.  Role of Osteogenesis in the Formation of Randall's Plaques , 2016, Anatomical record.

[33]  H. Park,et al.  HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs , 2015, Yonsei medical journal.

[34]  Wei-Chi Wang,et al.  Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. , 2015, The Journal of investigative dermatology.

[35]  W. Zhang,et al.  HLA‐B*58:01 is strongly associated with allopurinol‐induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case–control clinical study , 2015, The British journal of dermatology.

[36]  R. Unwin,et al.  Effect of being overweight on urinary metabolic risk factors for kidney stone formation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  G. Gambaro,et al.  Spontaneous calcification process in primary renal cells from a medullary sponge kidney patient harbouring a GDNF mutation , 2015, Journal of cellular and molecular medicine.

[38]  R. Abe.  Immunological response in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2015, The Journal of dermatology.

[39]  S. Aronoff,et al.  Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta‐analysis with meta‐regression of observational studies , 2015, International journal of dermatology.

[40]  A. Papp,et al.  Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. , 2014, Journal of the American Academy of Dermatology.

[41]  D. Huh,et al.  Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. , 2014, American journal of respiratory and critical care medicine.

[42]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[43]  D. Didona,et al.  Etanercept therapy for toxic epidermal necrolysis. , 2014, Journal of the American Academy of Dermatology.

[44]  F. Wang,et al.  Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[45]  H. Shimizu,et al.  An annexin A1–FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions , 2014, Science Translational Medicine.

[46]  M. Nichelatti,et al.  Guida Alla Lettura dei Risultati Della Metanalisi Dello Studio: “Medical Management to Prevent Recurrent Nephrolithiasis in Adults: A Systematic Review for an American College of Physicians Clinical Guideline” , 2014 .

[47]  V. Scott-Lang,et al.  Toxic Epidermal Necrolysis in a Child Successfully Treated with Infliximab , 2014, Pediatric dermatology.

[48]  W. Pichler,et al.  Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01 , 2014, The Journal of Immunology.

[49]  U. Amstutz,et al.  Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions , 2014, Epilepsia.

[50]  Y. L. Lim,et al.  The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre , 2013, The British journal of dermatology.

[51]  P. Wolkenstein,et al.  French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis , 2013 .

[52]  M. Gonçalo,et al.  HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population , 2013, The British journal of dermatology.

[53]  Takashi Sugamori,et al.  HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. , 2013, Journal of dermatological science.

[54]  P. Kwan,et al.  HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.

[55]  L. Naldi,et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.

[56]  G. Gambaro,et al.  When to suspect a genetic disorder in a patient with renal stones, and why. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[57]  G. Gambaro,et al.  Familial clustering of medullary sponge kidney is autosomal dominant with reduced penetrance and variable expressivity. , 2013, Kidney international.

[58]  H. Shimizu,et al.  Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. , 2013, The Journal of allergy and clinical immunology.

[59]  Dawn S. Milliner,et al.  Hereditary causes of kidney stones and chronic kidney disease , 2013, Pediatric Nephrology.

[60]  I. Bassukas,et al.  Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient , 2012, Case reports in dermatological medicine.

[61]  G. Capasso,et al.  Calcium nephrolithiasis, metabolic syndrome and the cardiovascular risk. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  Y.-C. Huang,et al.  The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta‐analysis , 2012, The British journal of dermatology.

[63]  H. Shimizu,et al.  Prolonged elevation of serum granulysin in drug‐induced hypersensitivity syndrome , 2012, The British journal of dermatology.

[64]  Yuan-Tsong Chen,et al.  Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. , 2012, The Journal of allergy and clinical immunology.

[65]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[66]  S. Mallal,et al.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.

[67]  N. Maalouf,et al.  Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. , 2012, The Journal of clinical endocrinology and metabolism.

[68]  G. Gambaro,et al.  Dietary habits in women with recurrent idiopathic calcium nephrolithiasis , 2012, Journal of Translational Medicine.

[69]  A. Trinchieri.  Development of a rapid food screener to assess the potential renal acid load of diet in renal stone formers (LAKE score). , 2012, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[70]  K. Sayama,et al.  Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2012, The British journal of dermatology.

[71]  Yuan-Tsong Chen,et al.  Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. , 2011, The Journal of allergy and clinical immunology.

[72]  Sang-Heon Cho,et al.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.

[73]  G. Koren,et al.  Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children , 2011, Pediatrics.

[74]  G. Vezzoli,et al.  Genetics and calcium nephrolithiasis. , 2011, Kidney international.

[75]  R. Jamal,et al.  Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. , 2011, Asian Pacific journal of allergy and immunology.

[76]  B. Moser,et al.  The Human Cutaneous Chemokine System , 2011, Front. Immun..

[77]  Q. Wang,et al.  Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland , 2011, Seizure.

[78]  J. Roujeau,et al.  Systematic review of treatments for Stevens–Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality , 2011, Therapeutic advances in drug safety.

[79]  Jacqueline Adam,et al.  Delayed drug hypersensitivity: models of T-cell stimulation. , 2011, British journal of clinical pharmacology.

[80]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[81]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[82]  Limei Zhao,et al.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.

[83]  T. Shiohara,et al.  Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? , 2011, The Journal of dermatology.

[84]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[85]  S. Murad,et al.  Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.

[86]  C. Sotozono,et al.  HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.

[87]  P. Kwan,et al.  Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China , 2010, Epilepsy & Behavior.

[88]  J. Roujeau,et al.  Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis , 2010, The British journal of dermatology.

[89]  G. Gambaro,et al.  Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[90]  S. Tiamkao,et al.  Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.

[91]  R. Hui,et al.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.

[92]  R. Cartotto,et al.  What Are the Fluid Requirements in Toxic Epidermal Necrolysis? , 2010, Journal of burn care & research : official publication of the American Burn Association.

[93]  L. Brochard,et al.  Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Epidemiology, Risk Factors, and Predictive Value of Skin Cultures , 2010, Medicine.

[94]  C. Joshi,et al.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.

[95]  H. Shimizu,et al.  Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. , 2009, Annals of internal medicine.

[96]  G. Gambaro,et al.  The origin of nephrocalcinosis, Randall's plaque and renal stones: a cell biology viewpoint. , 2009, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[97]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[98]  B. K. Park,et al.  Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. , 2009, Chemical research in toxicology.

[99]  E. Gubinelli,et al.  Toxic epidermal necrolysis successfully treated with etanercept , 2009, The Journal of dermatology.

[100]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[101]  R. Abe.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. , 2008, Journal of dermatological science.

[102]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[103]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[104]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[105]  A. Trinchieri.  Epidemiology of urolithiasis: an update. , 2008, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[106]  A. Luke,et al.  Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[107]  A. Kołtan,et al.  Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. , 2008, Acta dermato-venereologica.

[108]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[109]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[110]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[111]  Shui-Tein Chen,et al.  HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. , 2007, The Journal of allergy and clinical immunology.

[112]  G. Curhan.  Epidemiology of stone disease. , 2007, The Urologic clinics of North America.

[113]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[114]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[115]  G. Stingl,et al.  Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. , 2007, The Journal of investigative dermatology.

[116]  M. Pirmohamed,et al.  HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.

[117]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[118]  A. Trinchieri.  Epidemiological trends in urolithiasis: impact on our health care systems , 2006, Urological Research.

[119]  A. Trinchieri,et al.  Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers , 2006, Urological Research.

[120]  N. Yawalkar,et al.  Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment , 2005 .

[121]  C. Rubino,et al.  Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. , 2005, British journal of plastic surgery.

[122]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[123]  J. Cauley,et al.  Factors associated with the lumbar spine and proximal femur bone mineral density in older men , 2005, Osteoporosis International.

[124]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[125]  A. Roses,et al.  Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.

[126]  J. Roujeau,et al.  Evaluation of the potential role of cytokines in toxic epidermal necrolysis. , 2004, The Journal of investigative dermatology.

[127]  Martine Bagot,et al.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.

[128]  T. Bellón,et al.  Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. , 2004, The Journal of allergy and clinical immunology.

[129]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[130]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[131]  N. Abate,et al.  The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. , 2004, Kidney international.

[132]  D. Metry,et al.  Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. , 2003, Pediatrics.

[133]  W. Pichler,et al.  Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.

[134]  R. S. Padilla,et al.  Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study , 2003, Dermatology.

[135]  P. Friedmann,et al.  Mechanisms in cutaneous drug hypersensitivity reactions , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[136]  J. Tschopp,et al.  Intracellular Localization of Keratinocyte Fas Ligand Explains Lack of Cytolytic Activity under Physiological Conditions* , 2003, The Journal of Biological Chemistry.

[137]  H. Shimizu,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. , 2003, The American journal of pathology.

[138]  R. Paterson,et al.  Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. , 2003, The Journal of clinical investigation.

[139]  W. Pichler,et al.  Modes of presentation of chemical neoantigens to the immune system. , 2002, Toxicology.

[140]  W. Pichler.  Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.

[141]  A. Karagianni,et al.  Plasma exchange in patients with toxic epidermal necrolysis. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[142]  Martine Bagot,et al.  Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. , 2002, The Journal of investigative dermatology.

[143]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[144]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[145]  A. Shetty,et al.  Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. , 2000, The Journal of rheumatology.

[146]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[147]  F. Cappuccio,et al.  Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. , 2000, Journal of nephrology.

[148]  J. Roujeau,et al.  Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors , 2000, Clinical and experimental immunology.

[149]  F. Sjöberg,et al.  Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? , 1999, Intensive Care Medicine.

[150]  E. Rimm,et al.  Nephrolithiasis and Risk of Hypertension , 1999 .

[151]  J. Saffle,et al.  Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. , 1999, Journal of the American Academy of Dermatology.

[152]  M Pirmohamed,et al.  Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity , 1999, British journal of pharmacology.

[153]  W. Willett,et al.  Nephrolithiasis and risk of hypertension in women. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[154]  J. Tschopp,et al.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.

[155]  C. Jost,et al.  High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[156]  K. Takamori,et al.  A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[157]  E. Padovan,et al.  Molecular features of penicillin allergy. , 1998, The Journal of investigative dermatology.

[158]  L. Jefferson,et al.  Nutrition requirements in patients with toxic epidermal necrolysis. , 1997, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[159]  D. Loannides,et al.  Plasmapheresis in toxic epidermal necrolysis , 1997, International journal of dermatology.

[160]  I. McInnes,et al.  Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.

[161]  R. Low,et al.  High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall's plaque formation. , 1996, The Journal of urology.

[162]  R. Hiatt,et al.  Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. , 1996, American journal of epidemiology.

[163]  J. Roujeau,et al.  Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis , 1996, The British journal of dermatology.

[164]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[165]  A. Mason,et al.  Burn center care for patients with toxic epidermal necrolysis. , 1995, Journal of the American College of Surgeons.

[166]  D. Kok,et al.  Calcium oxalate nephrolithiasis, a free or fixed particle disease. , 1994, Kidney international.

[167]  A. Vanderkelen,et al.  Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. , 1994, Archives of dermatology.

[168]  O. Correia,et al.  Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. , 1993, Archives of dermatology.

[169]  E. Alexopoulos,et al.  Plasma Exchange (Pe) Treatment in Drug-Induced Toxic Epidermal Necrolysis (Ten) , 1991, The International journal of artificial organs.

[170]  E. Topol,et al.  Increased risk for abrupt closure during elective PTCA in the post-myocardial infarction period , 1991 .

[171]  J. Roujeau,et al.  Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. , 1987, Archives of dermatology.

[172]  G. Shires,et al.  Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without Corticosteroids , 1986, Annals of surgery.

[173]  B. Czarnetzki,et al.  Plasmapheresis in severe drug-induced toxic epidermal necrolysis. , 1985, Archives of dermatology.

[174]  C. M. Ginsburg.  Stevens-Johnson syndrome in children. , 1982, Pediatric infectious disease.

[175]  W. Robertson,et al.  Factors influencing the crystallisation of calcium oxalate in urine - critique , 1981 .

[176]  M. Peacock,et al.  Risk factors in calcium stone disease of the urinary tract. , 1978, British journal of urology.

[177]  A. Randall.  THE ORIGIN AND GROWTH OF RENAL CALCULI , 1937, Annals of surgery.

[178]  S. Mallal,et al.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. , 2018, The journal of allergy and clinical immunology. In practice.

[179]  S. Fook-Chong,et al.  Cyclosporine treatment for Stevens‐Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center , 2017, Journal of the American Academy of Dermatology.

[180]  M. A. Moreno Hidalgo,et al.  Significant HLA class I type associations with aromatic antiepileptic drug (AED)‐induced SJS/TEN are different from those found for the same AED‐induced DRESS in the Spanish population , 2017, Pharmacological research.

[181]  Piyush Kumar,et al.  Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality. , 2016, Dermatology online journal.

[182]  Ferraro Pietro Manuel,et al.  Randall’s plaques, plugs and the clinical workup of the renal stone patient , 2014, Urolithiasis.

[183]  D. Longo,et al.  Necroptosis. , 2014, The New England journal of medicine.

[184]  C. Serrano-Reyes,et al.  Toxic epidermal necrolysis successfully treated with infliximab. , 2013, Journal of investigational allergology & clinical immunology.

[185]  O. Faye,et al.  Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg) , 2012, Drugs.

[186]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[187]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[188]  M. Jonkman,et al.  Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2007, Acta dermato-venereologica.

[189]  W. Pichler,et al.  Pharmacological interaction of drugs with immune receptors: the p-i concept. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[190]  O. Faye,et al.  Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. , 2005, Drugs.

[191]  R. Gamelli,et al.  Toxic epidermal necrolysis: does immunoglobulin make a difference? , 2004, The Journal of burn care & rehabilitation.

[192]  J. Hawk,et al.  Rook's Textbook of Dermatology. , 2004 .

[193]  J. Roujeau,et al.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. , 2003, Archives of dermatology.

[194]  F. Muldowney.  Prevention of recurrent stones in idiopathic hypercalciuria. , 2002, The New England journal of medicine.

[195]  J. Roujeau,et al.  Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. , 2002, Archives of dermatology.

[196]  H. Tiselius.  Metabolic evaluation of patients with stone disease. , 1997, Urologia internationalis.

[197]  T. Meschi,et al.  URINARY VOLUME, WATER AND RECURRENCES IN IDIOPATHIC STUDY CALCIUM NEPHROLITHIASIS: A &YEAR RANDOMIZED PROSPECTIVE , 1996 .

[198]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.